Form 4: SCPharmaceuticals Director Bonstein Acquires Stock Options
SEC Form 4 Filing
Director Sara Bonstein acquired 19,750 stock options in scPharmaceuticals Inc. on June 11, 2024.
Summary
- Sara Bonstein, a director of scPharmaceuticals Inc., acquired 19,750 stock options on June 11, 2024.
- The options have an exercise price of $4.11.
- The stock options vest in full upon the earlier of June 11, 2025, or the next annual meeting of the Issuer's stockholders.
- The options expire on June 11, 2034.
- Following the transaction, Bonstein directly owns 19,750 derivative securities.
Sentiment
Score: 5
Explanation: This is a neutral event, simply reporting the acquisition of stock options by a director. It doesn't inherently indicate positive or negative sentiment.
Industry Context
This is a standard SEC Form 4 filing, indicating a change in beneficial ownership of securities by a company insider. It's a routine part of corporate governance and provides transparency to the market.
Stakeholder Impact
- The acquisition of stock options by a director could be viewed positively by shareholders as it aligns the director's interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| 06/11/2024 | Date of transaction: Sara Bonstein acquired stock options. |
| 06/11/2025 | Earliest vesting date for the stock options. |
| 06/11/2034 | Expiration date of the stock options. |
| 06/13/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.